Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

U.S. Senator Bernie Sanders sent Moderna Inc a letter this week asking the drug company to halt planned U.S. price increases on its COVID-19 vaccine, saying price hikes could make the shot unaffordable for millions of Americans.

Sen. Sanders asks Moderna not to hike COVID vaccine price

Moderna Therapeuitics Inc is mulling a hike in the US price of its Covid-19 vaccine to between US$110 to $130 a shot as government contracts come to an end, chief executive Stephane Bancel said in an interview yesterday. That would be well above previous guidance, which had indicated a range of US$64-US$100 per jab.

Moderna mulls Covid vaccine price hike as infections rise

Moderna, Inc. (NASDAQ:MRNA ) 41st Annual J.P. Morgan Healthcare Conference January 9, 2023 5:15 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Jessica Fye - J.P Morgan Jessica Fye Hey, good afternoon, everyone.

Moderna, Inc. (MRNA) 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Shares of Moderna Inc. MRNA, +2.39% were up 2.5% in trading on Monday afternoon after the Wall Street Journal reported that the company is considering pricing its COVID-19 vaccine at $110 to $130 per dose. That's the same price range that Pfizer Inc. PFE, -4.57% and BioNTech BNTX, -0.11%  suggested for their COVID vaccine once the COVID vaccines move into a commercial market.

WSJ: Moderna may charge up to $130 per dose of its COVID shot

The commercial price for the shot is similar to Pfizer's plans for after government contracting ends.

Moderna Considers Price of $110-$130 for Covid-19 Vaccine

CureVac B.V

Ocugen, Inc.

A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.

Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response

Shares of Moderna Inc. MRNA, +3.94% were up about 1.0% in premarket trading on Monday after the company reiterated that it expects to have $5.0 billion in sales of its COVID-19 vaccine in 2023. Moderna also said its vaccine generated $18.4 billion in sales in 2022, and the company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022.

Moderna's COVID shot to generate $5.0 billion in sales in 2023

COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited) Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023 Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing R&D investment to an expected $4.5 billion for 2023 Pivotal Phase 3 RSV study of mRNA-1345 in older adults ( ≥ 60 yrs.) has now accrued the cases required to complete our first interim efficacy analysis Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients.

Moderna Announces Advances Across mRNA Pipeline and Provides Business Update

Etsy

Vertex Pharmaceuticals

Over time, some of last year's losers could win big.

Looking for Growth in 2023? Where to Invest $5,000

CytomX Therapeutics

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

On a resoundingly positive Friday for the market, CytomX Therapeutics (NASDAQ: CTMX ) is providing a large portion of the fireworks. Specifically, CTMX stock skyrocketed more than 50% before settling at a 40% increase as of this writing.

CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal

Moderna's vaccine earnings are helping it prepare for the future.

Many Investors Wouldn't Touch This Stock With a 10-Foot Pole Last Year. Here's Why It's a Buy in 2023.

CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics” with Moderna.

CytomX shares surge more than 50% on Moderna partnership

Moderna Inc on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics to work on messenger RNA-based therapies for a wide range of diseases.

Moderna signs $35 million deal with cancer drug developer CytomX

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform. The research collaboration will leverage core scientific advances at Moderna and CytomX.

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

Moderna (MRNA) announced it is buying OriCiro Genomics K.K. These are the details.

Moderna Buying Genomics K.K. For $85 Million (MRNA)

Moderna Inc, the biotech pioneering messenger RNA (mRNA) therapeutics and vaccines, said it has struck a deal to buy Japan-based OriCiro Genomics for US$85 million to boost its manufacturing capabilities.  "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, the CEO of Moderna, in a statement.

Moderna to buy Japan-based OriCiro Genomics for US$85M

The small Tokyo-based company's tools will help the pharma giant's messenger RNA manufacturing process.

Moderna Bolsters Its Vaccine Pipeline With $85 Million Deal for Biotech Firm OriCiro

Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's messenger RNA (mRNA) manufacturing capabilities.

Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million.

Moderna to Acquire OriCiro Genomics

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the 41st annual J.P. Morgan Healthcare Conference on Monday, January 9th at 5:15 p.m.

Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

Tesla

Accenture Plc

Arista Networks

Broadcom

Carrier Global

Charter Communications

In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.

Tesla is not alone: 18 (and a half) other big stocks are headed for their worst year on record

News for Moderna Stock (MRNA)